← Evidence map

ArticleCNS drugs2026

A 12-Week, Open-Label, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Lemborexant in Patients with Insomnia Comorbid with Depressive Episodes (SELENADE).

Yoshikazu Takaesu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2026

this papercites it

A 12-Week, Open-Label, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Lemborexant in Patients with Insomnia Comorbid with Depressive Episodes (SELENADE). | OpenQuestion